Andrei V Chistyakov1, Bella Kreinin2, Sara Marmor2, Boris Kaplan1, Adel Khatib2, Nawaf Darawsheh2, Danny Koren2, Menashe Zaaroor1, Ehud Klein3. 1. Department of Neurosurgery, Rambam Medical Center, B. Rappaport Faculty of Medicine, The Technion, Israel Institute of Technology, Haifa, Israel. 2. Department of Psychiatry, Rambam Medical Center, B. Rappaport Faculty of Medicine, The Technion, Israel Institute of Technology, Haifa 31096, Israel. 3. Department of Psychiatry, Rambam Medical Center, B. Rappaport Faculty of Medicine, The Technion, Israel Institute of Technology, Haifa 31096, Israel. Electronic address: e_klein@rambam.health.gov.il.
Abstract
BACKGROUND:Theta-burst transcranial magnetic stimulation (TBS) has been shown to induce potent and long lasting effects on cortical excitability. In a previous open study, we demonstrated safety, tolerability and antidepressant properties of continuous TBS (cTBS) in major depression (MD). The present study was aimed to evaluate the therapeutic efficacy of cTBS in depressed patients using a double-blind, sham-controlled design. METHODS:Twenty nine patients with MD were randomized to receive either active cTBS to the right dorsolateral prefrontal cortex (n=15) or shamcTBS (n=14) for 10 consecutive work days. After the 10th session, patients who received sham TBS were crossed over to active cTBS which consisted of 10 daily sessions. Patients who received active cTBS continued with the same treatment protocol for additional 10 treatments. Each treatment session consisted of 3600 stimuli at an intensity of 100% of the active motor threshold. Severity of depression was assessed weekly. RESULTS: Overall, there was no significant difference in the degree of clinical improvement between active and sham cTBS groups. However, in patients whose medication status remained unchanged before the trial (n=8) and in those who were medication-free (n=3), active cTBS resulted in a significantly greater reduction of Hamilton depression scores as compared to sham cTBS. LIMITATIONS: A small sample size, confounding effect of medication and short treatment period. CONCLUSIONS: Our results suggest that the antidepressant effect of cTBS is modest, yet it might be beneficial to patients nonresponsive to ongoing pharmacological treatment. A direct comparison between cTBS and conventional rTMS protocols is warranted.
RCT Entities:
BACKGROUND: Theta-burst transcranial magnetic stimulation (TBS) has been shown to induce potent and long lasting effects on cortical excitability. In a previous open study, we demonstrated safety, tolerability and antidepressant properties of continuous TBS (cTBS) in major depression (MD). The present study was aimed to evaluate the therapeutic efficacy of cTBS in depressedpatients using a double-blind, sham-controlled design. METHODS: Twenty nine patients with MD were randomized to receive either active cTBS to the right dorsolateral prefrontal cortex (n=15) or sham cTBS (n=14) for 10 consecutive work days. After the 10th session, patients who received sham TBS were crossed over to active cTBS which consisted of 10 daily sessions. Patients who received active cTBS continued with the same treatment protocol for additional 10 treatments. Each treatment session consisted of 3600 stimuli at an intensity of 100% of the active motor threshold. Severity of depression was assessed weekly. RESULTS: Overall, there was no significant difference in the degree of clinical improvement between active and sham cTBS groups. However, in patients whose medication status remained unchanged before the trial (n=8) and in those who were medication-free (n=3), active cTBS resulted in a significantly greater reduction of Hamilton depression scores as compared to sham cTBS. LIMITATIONS: A small sample size, confounding effect of medication and short treatment period. CONCLUSIONS: Our results suggest that the antidepressant effect of cTBS is modest, yet it might be beneficial to patients nonresponsive to ongoing pharmacological treatment. A direct comparison between cTBS and conventional rTMS protocols is warranted.
Authors: Roumen V Milev; Peter Giacobbe; Sidney H Kennedy; Daniel M Blumberger; Zafiris J Daskalakis; Jonathan Downar; Mandana Modirrousta; Simon Patry; Fidel Vila-Rodriguez; Raymond W Lam; Glenda M MacQueen; Sagar V Parikh; Arun V Ravindran Journal: Can J Psychiatry Date: 2016-08-02 Impact factor: 4.356
Authors: A Irem Sonmez; Deniz Doruk Camsari; Aiswarya L Nandakumar; Jennifer L Vande Voort; Simon Kung; Charles P Lewis; Paul E Croarkin Journal: Psychiatry Res Date: 2018-12-07 Impact factor: 3.222
Authors: Shawn M McClintock; Irving M Reti; Linda L Carpenter; William M McDonald; Marc Dubin; Stephan F Taylor; Ian A Cook; John O'Reardon; Mustafa M Husain; Christopher Wall; Andrew D Krystal; Shirlene M Sampson; Oscar Morales; Brent G Nelson; Vassilios Latoussakis; Mark S George; Sarah H Lisanby Journal: J Clin Psychiatry Date: 2018 Jan/Feb Impact factor: 4.384
Authors: Diego Freitas Tavares; Paulo Suen; Carla Garcia Rodrigues Dos Santos; Doris Hupfeld Moreno; Leandro Da Costa Lane Valiengo; Izio Klein; Lucas Borrione; Pamela Marques Forte; André R Brunoni; Ricardo Alberto Moreno Journal: Neuropsychopharmacology Date: 2021-06-30 Impact factor: 7.853